Overall, however, few comparative studies are available with other agents currently used for the management of BPH, particularly the a 1 -adrenoceptor blockers. In view of this, Serenoa repens will probably be used as an alternative to the better established agents, a 1 -adrenoceptor blockers and finasteride. Although there was no significant difference between the 2 groups in the treatment options selected, patients in the SDP group were significantly better informed about BPH than control patients at 2 weeks after enrolment. The SDP group was also significantly more satisfied with the decision-making process at 3 and 12 months. General health and physical functioning remained stable among patients in the SDP group but deteriorated among control patients.
Contents Click a heading to go to that section.
Click the to return here. 199.55 201.40 a Includes hesitancy, impairment of size or force of urinary stream, interruption of urinary stream and terminal dribbling. For 28 days' treatment at usual maintenance dosage. Urological Sciences Research Foundation . Non-profit organization specializing in prostate research.